Publication:
Inactivation of human plasma alters the structure and biomechanical properties of engineered tissues.

dc.contributor.authorRosell-Valle, Cristina
dc.contributor.authorMartín-López, María
dc.contributor.authorCampos, Fernando
dc.contributor.authorChato-Astrain, Jesús
dc.contributor.authorCampos-Cuerva, Rafael
dc.contributor.authorAlaminos, Miguel
dc.contributor.authorSantos González, Mónica
dc.date.accessioned2023-05-03T13:38:57Z
dc.date.available2023-05-03T13:38:57Z
dc.date.issued2022-08-23
dc.description.abstractFibrin is widely used for tissue engineering applications. The use of blood derivatives, however, carries a high risk of transmission of infectious agents, necessitating the application of pathogen reduction technology (PRT). The impact of this process on the structural and biomechanical properties of the final products is unknown. We used normal plasma (PLc) and plasma inactivated by riboflavin and ultraviolet light exposure (PLi) to manufacture nanostructured cellularized fibrin-agarose hydrogels (NFAHs), and then compared their structural and biomechanical properties. We also measured functional protein C, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and coagulation factors [fibrinogen, Factor (F) V, FVIII, FX, FXI, FXIII] in plasma samples before and after inactivation. The use of PLi to manufacture cellularized NFAHs increased the interfibrillar spacing and modified their biomechanical properties as compared with cellularized NFAH manufactured with PLc. PLi was also associated with a significant reduction in functional protein C, FV, FX, and FXI, and an increase in the international normalized ratio (derived from the PT), APTT, and TT. Our findings demonstrate that the use of PRT for fibrin-agarose bioartificial tissue manufacturing does not adequately preserve the structural and biomechanical properties of the product. Further investigations into PRT-induced changes are warranted to determine the applications of NFAH manufactured with inactivated plasma as a medicinal product.
dc.identifier.doi10.3389/fbioe.2022.908250
dc.identifier.issn2296-4185
dc.identifier.pmcPMC9445835
dc.identifier.pmid36082161
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445835/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fbioe.2022.908250/pdf
dc.identifier.urihttp://hdl.handle.net/10668/20524
dc.journal.titleFrontiers in bioengineering and biotechnology
dc.journal.titleabbreviationFront Bioeng Biotechnol
dc.language.isoen
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.organizationFundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla-FISEVI
dc.organizationFundación Pública Andaluz Progreso y Salud-FPS
dc.organizationC.T.S. Sevilla
dc.page.number908250
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectbioartificial skin
dc.subjectbiomechanical properties
dc.subjectfibrin-agarose hydrogel
dc.subjectpathogen reduction method
dc.subjecttissue engineering
dc.titleInactivation of human plasma alters the structure and biomechanical properties of engineered tissues.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number10
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9445835.pdf
Size:
1.5 MB
Format:
Adobe Portable Document Format